BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 4, 2005
View Archived Issues
CoTherix Gets Approval For Inhaled PAH Drug Ventavis
Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. (BioWorld Today)
Read More
Chemokine Therapeutics IPO: C$16M For Two Lead Drugs
Read More
What's Wrong At The FDA? The System, Says One Critic
Read More
OpGen's New CEO Focusing On Optical Mapping Platform Growth
Read More
Holiday notice
Read More
Other News To Note
Read More